• Gilead Sciences (GILD.BA) is trading 2% up today at $48540.00.
  • The European Commission granted marketing authorization for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (TNBC) patients not candidates for PD-1 or PD-L1 inhibitor therapy.
  • Investors are also continuing to digest recent HIV pipeline milestones, including the FDA's acceptance of Gilead’s Yeztugo HIV prevention filing and positive Phase 3 data for lenacapavir-based regimens.